ACIP recommends pentavalent meningococcal vaccine Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for individuals 10 through 25 years of age.

Two systematic reviews and meta-analyses found evidence that OMV-based meningococcal B vaccines offer moderate ...

Pilgrims are also urged to ensure they are up to date with other nationally recommended vaccinations. Read more at ...

SINGAPORE: All Singapore Haj pilgrims travelling to Saudi Arabia in June are required to be vaccinated for influenza and ...

Alyson Hannigan, Ask2BSure spokesperson, actress, and mom, stars in an Ask2BSure campaign video to raise awareness about ...

Immunization is one of the most cost-effective public health interventions in history. Backed by extensive global and local data, the impact of vaccines on healthcare systems and populations is clear ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

Barroso looks back at Gavi’s 25-year-old journey; and the changes he foresees in Gavi’s role in helping countries in the ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

The Kansas Department of Health and Environment (KDHE) in its weekly update reported 2 more measles cases today, lifting the ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...